DCA Inc. dba Beacon Prescriptions MARCS-CMS 525833 —
- Delivery Method:
- VIA Electronic Mail
- Reference #:
Recipient NameAnnik S. Chamberlin
- DCA Inc. dba Beacon Prescriptions
690 North Main Street
Southington, CT 06489-2529
- Issuing Office:
- OPQO Division I / New Jersey District
- (973) 331-4900
Dear Dr. Chamberlin:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #525833], dated June 1, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
If you have any questions, contact Compliance Officer Juan Jimenez at firstname.lastname@example.org; and email@example.com. Please identify correspondence with FEI # 3005823862.
Program Division Director/District Director
U.S. Food and Drug Administration
OPQO Division I / New Jersey District
Digitally signed by Diana Amador-toro -S
DN: c=US, o=U.S. Government, ou=HHS,